Indian pharma deals landscape shaped by Covid-19
The number of deals made in the Indian pharma market increased by 22% from 2019 to 2020, likely due to…
By
Markets
Latest in
Markets
Why Covid-19 didn’t hurt tech brands’ appetite for Asian investment
Companies have reason to be sceptical about investing in Asia in general and in China in particular. But Asia investment…
Novartis aiming to expand patient reach for world’s most expensive drug, Zolgensma
The US FDA's clinical hold on Zolgensma did not just delay Novartis in developing the drug, but allowed its competitors…
By
Microbiome-targeting pipeline addresses multiple immunological indications
The microbiome-targeting pipeline holds numerous potential candidates, with most still in the early stages of drug development.
By
EHA 2021: primary endpoints met in final analysis of EURO-SKI trial in CML
Results from the EURO-SKI trial suggest tyrosine kinase inhibitor treatment duration and deep molecular response duration could be important prognostic…
By
Novavax’s Covid-19 vaccine may face severe uptake challenges in the US
Due to decreasing vaccination rates and high supplies of mRNA vaccines, Novavax may not experience much uptake of its Covid-19…
By
Interim data from tenapanor’s OPTIMIZE trial signals promising option for CKD-HP
GlobalData expects Ardelyx's tenapanor to gain a frontline position in the chronic kidney disease–hyperphosphataemia (CKD-HP) market due to its novel…
By
Covid-19 vaccine purchasing in EU likely to pivot to traditional reimbursement models from 2023
From 2023, Covid-19 vaccine manufacturers are likely to have to navigate each European Union (EU) member state's traditional reimbursement framework,…
By